CoronaryAtlas logo
CoronaryAtlas
Tissue factor pathway inhibitor
Pathway / Coagulation & thrombus formation

Tissue factor pathway inhibitor

TFPIprotein

Tissue factor pathway inhibitor antagonizes coagulation activation and thrombus formation, with inverse association to MI risk.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleNatural anticoagulant inhibiting tissue-factor-triggered coagulation and thrombin generation.
Druggability
DruggableYes
Known drugs / candidates4
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000003436

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
100
A — assay feasibility
72
E — evidence strength
42
T1DI (composite)
2
Specificity differential (R−C)-85
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 3
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressmag 3
Coverage: 2/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 2 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(11)